Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update

—ARIKAYCE® Total Revenue of $79.1 Million for the Third Quarter of 2023 Reflects Highest Quarter of Sales Since Launch and 17% Growth Compared to the Third Quarter of 2022—
—Company...

Related Keywords

New Jersey ,United States ,Japan ,Japanese ,Pharma Gmb ,Will Lewis ,Bryan Dunn ,Eleanor Barisser ,Mandy Fahey ,Company Reiterates ,Company Annual Report On Form ,Exchange Commission ,Drug Administration ,Stage Research ,Regional Poison Control Center ,Prnewswire Insmed Incorporated Nasdaq ,Insmed Incorporated ,Corporate Communications ,Total Revenue ,Third Quarter ,Highest Quarter ,Sales Since Launch ,Growth Compared ,Company Reiterates Full Year ,Insmed Shares Encouraging Blended ,Blinded Dose Titration ,Tolerability Data ,Blinded Pulmonary Vascular Resistance ,Topline Data ,Adult Patients ,Bronchiectasis Remains ,Read Out ,Second Quarter ,Chief Executive Officer ,Data Safety ,Monitoring Board ,Financial Guidance ,Investor Relations ,Nebuliser Dispersion ,Nebulizer System ,Hypersensitivity Reactions ,Fetal Toxicity ,Common Adverse Reactions ,Full Prescribing ,Private Securities Litigation Reform Act ,Pharmakon Advisors ,Orbimed Royalty ,Annual Report ,Markets ,